Elevance Health, Inc. Reaffirms 2026 Earnings Guidance Amid Potential CMS Sanctions

Key Highlights from the 8-K Filing

• Elevance Health, Inc. (NYSE: ELV) reaffirms its adjusted shareholders’ earnings guidance for full year 2026 to be at least \$25.50 per diluted share.
• The Company also maintains its 2026 benefit expense ratio guidance at 90.2%, plus or minus 50 basis points.
• Elevance Health is facing potential intermediate sanctions from the Centers for Medicare & Medicaid Services (CMS), which could impact new enrollments and communications for its Medicare Advantage-Prescription Drug plans.
• The Company’s earnings guidance already includes the estimated impact of these potential sanctions.
• The Company is unable to provide a reconciliation of its adjusted earnings guidance to GAAP earnings due to uncertainties around potential financial payments related to the CMS matter.

Details Investors Should Not Miss

1. Reaffirmation of 2026 Financial Guidance:

Elevance Health’s leadership will hold meetings with investors and analysts over the upcoming week, during which they will reaffirm their outlook for 2026. The company expects adjusted shareholders’ earnings to be at least \$25.50 per diluted share for the full year. Additionally, the benefit expense ratio is projected at 90.2%, with a potential variance of 50 basis points in either direction.

2. Potential CMS Sanctions:

On February 27, 2026, Elevance Health received notice from CMS of its intent to impose intermediate sanctions. These sanctions would:

• Suspend the enrollment of Medicare beneficiaries into Elevance’s Medicare Advantage-Prescription Drug plans.
• Suspend certain communication activities with Medicare beneficiaries.
• The sanctions would become effective as of March 31, 2026, unless CMS determines that Elevance Health has satisfactorily addressed the identified issues.

This development is particularly material for shareholders, as it could have a direct impact on revenue from new enrollments and potentially harm the company’s reputation in the Medicare market.

3. Guidance Includes Impact of Sanctions:

The company has stated that its adjusted earnings guidance for 2026 already factors in the impact of these potential sanctions, if imposed. However, management also disclosed that it is unable to provide a reconciliation to GAAP earnings guidance at this time because it cannot reasonably estimate the impact of any potential financial penalties or payments that may be required to resolve the CMS matter.

4. Forward-Looking Statements and Risks:

The company’s filing includes comprehensive cautionary language regarding forward-looking statements. Risks highlighted include:

• Trends in healthcare costs and utilization rates.
• Potential reduced enrollment, especially if sanctions are imposed.
• Regulatory changes and their enforcement.
• The impact of large-scale medical emergencies, cyber-attacks, and data security incidents.
• Competition for employees and risks associated with international operations.
• Potential events affecting the company’s licenses with the Blue Cross and Blue Shield Association.

Potential Share Price Impact

This disclosure is highly price sensitive for Elevance Health shareholders and the broader market:

• The reaffirmation of robust 2026 earnings guidance demonstrates management’s confidence in the company’s underlying operations, even in the face of significant regulatory challenges.
• However, the risk of CMS-imposed sanctions—especially those that would halt new Medicare enrollments and limit member communications—introduces substantial uncertainty. These sanctions could negatively affect membership growth, revenue, and overall market sentiment toward the stock.
• The inability to reconcile adjusted to GAAP earnings due to potential, but currently unquantifiable, financial penalties heightens the uncertainty for investors.
• Resolution of the CMS issues or avoidance of sanctions could result in positive share price movement, while confirmation and enforcement of sanctions could have the opposite effect.

Other Corporate Details

• Company Name: Elevance Health, Inc.
• Trading Symbol: ELV
• Exchange: NYSE
• Principal Executive Offices: 220 Virginia Avenue, Indianapolis, IN 46204
• Company is not classified as an “Emerging Growth Company” under SEC rules.

Conclusion

Investors should closely monitor further updates from Elevance Health regarding the status of the CMS sanctions. Any resolution, escalation, or additional financial disclosures could drive significant share price volatility in the near term.

Disclaimer: This article is a summary and analysis of Elevance Health, Inc.’s SEC Form 8-K filing dated March 10, 2026. It is for informational purposes only and does not constitute investment advice. Investors should conduct their own research and consider consulting a qualified financial advisor before making investment decisions. The author and publisher are not responsible for any actions taken based on this information.

View Elevance Health, Inc. Historical chart here